Bayer Alleges J&J's Claims Regarding NUBEQA are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
February 24, 2026
February 24, 2026
WHIPPANY, New Jersey, Feb. 24 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news on Feb. 23, 2026:
* * *
Bayer Alleges J&J's Claims Regarding NUBEQA(R) are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
Bayer files false advertising suit against J&J and Janssen Biotech
* Lawsuit seeks preliminary and permanent injun . . .
* * *
Bayer Alleges J&J's Claims Regarding NUBEQA(R) are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
Bayer files false advertising suit against J&J and Janssen Biotech
* Lawsuit seeks preliminary and permanent injun . . .